ArticleNature cancer2021
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05273541 (Beijing 302 Hospital), which is not on this map. Cited by 45 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05273541 phase1 / phase2unknown statusnot on this mapstarted 2022, after this paper: background citation
Beijing 302 Hospital
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: A systematic review.Immunity, inflammation and disease · 2024Pooled it
- AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants.European journal of cancer (Oxford, England : 1990) · 2023Guideline
- Factors influencing Anti-SARS-CoV-2 IgG levels after vaccination in breast cancer patients.Discover oncology · 2026Article
- Delayed but successful development of immune memory against SARS-COV-2 after B cell-depleting monotherapy.Infection · 2025Observational
- Dysregulated Adaptive Immune Responses to SARS-CoV-2 in Immunocompromised Individuals.Microorganisms · 2025Article
- Article
- mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer.Journal for immunotherapy of cancer · 2024Article
- Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.Leukemia · 2024Article
- Identifying immune checkpoints on dysregulated T-cells as prognostic biomarkers for multiple myeloma patients with COVID-19.Frontiers in immunology · 2024Article
- Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.Leukemia · 2024Article
- SARS-CoV-2 Infection, Vaccination and Risk of Death in People with An Oncological Disease in Northeast Italy.Journal of personalized medicine · 2023Article
- COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.The Journal of infectious diseases · 2023Review
- A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).Scientific reports · 2023Article
- The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic.Pathogens (Basel, Switzerland) · 2023Review
- The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment.The oncologist · 2023Article
- Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies.International journal of clinical oncology · 2023Article
- Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium.Lancet regional health. Americas · 2023Article
- Review
- SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants.Pathogens (Basel, Switzerland) · 2023Review
- Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.JAMA oncology · 2023Article
Corrections and comments
- Commented on by
- Update of
Authors and funding
89 authors at 6 institutions in 2 countries.
Annika Fendler *Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-7267-0981
Lewis Au *Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-5877-8657
Scott T C Shepherd *Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-6208-173X
Fiona ByrneCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
Maddalena CerroneTuberculosis Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-6900-6086
Laura Amanda BoosSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Karolina RzeniewiczCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
William GordonCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-8166-2641
Benjamin ShumCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
Camille L GerardCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
Barry WardCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
Wenyi XieCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
Andreas M SchmittSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Nalinie Joharatnam-HoganSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Georgina H CornishRetroviral Immunology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1984-6677
Martin PuleDepartment of Haematology, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-8347-9867
Leila MekkaouiAutolus Ltd., London, UK.ORCID http://orcid.org/0000-0001-8640-840X
Kevin W NgRetroviral Immunology Laboratory, The Francis Crick Institute, London, UK.
Eleanor CarlyleSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Kim EdmondsSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Lyra Del RosarioSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Sarah SarkerSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Karla LingardSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Mary MangwendeSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Lucy HoltSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Hamid AhmodSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Richard StoneExperimental Histopathology Laboratory, The Francis Crick Institute, London, UK.
Camila GomesExperimental Histopathology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-2094-8141
Helen R FlynnMass Spectrometry Proteomics Science Technology Platform, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-7002-9130
Ana Agua-DoceFlow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, UK.
Philip HobsonFlow Cytometry Scientific Technology Platform, The Francis Crick Institute, London, UK.
Simon CaidanSafety, Health and Sustainability, The Francis Crick Institute, London, UK.
Michael HowellHigh Throughput Screening Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-0912-0079
Mary WuHigh Throughput Screening Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-2074-6171
Robert GoldstoneAdvanced Sequencing Facility, The Francis Crick Institute, London, UK.
Margaret CrawfordAdvanced Sequencing Facility, The Francis Crick Institute, London, UK.
Laura CubittAdvanced Sequencing Facility, The Francis Crick Institute, London, UK.
Harshil PatelDepartment of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-2707-7940
Mike GavrielidesScientific Computing Scientific Technology Platform, The Francis Crick Institute, London, UK.
Emma NyeExperimental Histopathology Laboratory, The Francis Crick Institute, London, UK.
Ambrosius P SnijdersMass Spectrometry Proteomics Science Technology Platform, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-5416-8592
James I MacRaeMetabolomics Scientific Technology Platform, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1464-8583
Jerome NicodAdvanced Sequencing Facility, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-2459-3480
Firza GronthoudDepartment of Pathology, The Royal Marsden NHS Foundation Trust, London, UK.
Robyn L SheaDepartment of Pathology, The Royal Marsden NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-7596-4555
Christina MessiouDepartment of Radiology, The Royal Marsden NHS Foundation Trust, London, UK.
David CunninghamGastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, London, UK.ORCID http://orcid.org/0000-0001-5158-1069
Ian ChauGastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, London, UK.ORCID http://orcid.org/0000-0003-0286-8703
Naureen StarlingGastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, London, UK.
Nicholas TurnerBreast Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Liam WelshNeuro-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Nicholas van AsClinical Oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Robin L JonesSarcoma Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
Joanne DroneyPalliative Medicine, The Royal Marsden NHS Foundation Trust, London, UK.
Susana BanerjeeGynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Kate C TathamAnaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0003-3080-8011
Shaman JhanjiAnaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-1116-628X
Mary O'BrienLung Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Olivia CurtisLung Unit, The Royal Marsden NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-1509-7023
Kevin HarringtonHead and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-6014-348X
Shreerang BhideHead and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Jessica BazinHaemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Anna RobinsonHaemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Clemency StephensonHaemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Tim SlatterySkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Yasir KhanSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Zayd TippuSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Isla LeslieSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Spyridon GennatasAcute Oncology Service, The Royal Marsden NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-5635-7696
Alicia OkinesBreast Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Alison ReidUro-oncology Unit, The Royal Marsden NHS Foundation Trust, Surrey, UK.
Kate YoungSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Andrew J S FurnessSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Lisa PickeringSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0002-7579-340X
Sonia GandhiNeurodegeneration Biology Laboratory, The Francis Crick Institute, London, UK.
Steve GamblinStructural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-5331-639X
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-4299-3018
Crick COVID-19 Consortium
Emma NicholsonHaemato-oncology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Sacheen KumarGastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey, London, UK.ORCID http://orcid.org/0000-0002-4692-4554
Nadia YousafLung Unit, The Royal Marsden NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0003-2090-0025
Katalin A WilkinsonTuberculosis Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-9796-2040
Anthony SwerdlowDivision of Genetics and Epidemiology and Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
Ruth HarveyWorldwide Influenza Centre, The Francis Crick Institute, London, UK.
George KassiotisRetroviral Immunology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-8457-2633
James LarkinSkin and Renal Units, The Royal Marsden NHS Foundation Trust, London, UK.
Robert J WilkinsonTuberculosis Laboratory, The Francis Crick Institute, London, UK.
Samra TurajlicCancer Dynamics Laboratory, The Francis Crick Institute, London, UK. samra.turajlic@crick.ac.uk.ORCID http://orcid.org/0000-0001-8846-136X
CAPTURE consortium
Royal Marsden NHS Foundation Trust · GBThe Francis Crick Institute · GBAutolus (United Kingdom) · GBGuy's Hospital · GBInstitute of Cancer Research · GBLondon Cancer · GB
Funding
Deciphering Clonal Evolution in Hereditary Renal Cell CarcinomasU01CA247439 · NCI · FRANCIS CRICK INSTITUTE, LTD · PI TURAJLIC, SAMRA · 2020 to 2024
$1.1MCancer Research UK 18176Cancer Research UK 29911NCI NIH HHS U01 CA247439
Abstract
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4
Indexed as
AdolescentAdultAgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralCOVID-19FemaleFollow-Up StudiesHumansImmunity, CellularMaleMiddle AgedNeoplasmsProspective StudiesSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT05273541ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.